ClinicalTrialStartPulse / compare
Merck Sharp & Dohme LLC vs Pfizer: ClinicalTrialStartPulse comparison
Merck Sharp & Dohme LLC's enrollment of 1,104 is 1.0x Pfizer's 1,100 (95th percentile). Merck Sharp & Dohme LLC is dated 2026-11-03; Pfizer 2026-10-09.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
Both records plus every comparable US record, with all columns and source links · Card, Apple Pay, Google Pay or Link via Stripe
How does Merck Sharp & Dohme LLC compare to Pfizer?
| Field | Merck Sharp & Dohme LLC | Pfizer |
|---|---|---|
| Sponsor | Merck Sharp & Dohme LLC | Pfizer |
| Sponsor type | Industry (pharma, biotech, medtech) | Industry (pharma, biotech, medtech) |
| Study | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) | A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma |
| NCT ID | NCT07705607 | NCT07869043 |
| Phase | Phase 3 | Phase 3 |
| Status | recruiting | recruiting |
| Conditions | Diabetic Retinopathy; Macular Edema | Asthma |
| Intervention types | drug | drug, other |
| Target enrollment | 1104 | 1100 |
| Site countries | United States | United States |
| Posted | 2026-07-15 | 2026-10-09 |
| Planned start | 2026-09-25 | 2026-09-30 |
| Event | Started recruiting | Newly registered study |
| Event date | 2026-09-25 | 2026-10-09 |
| Last update posted | 2026-11-03 | |
| enrollment percentile | 95th | 95th |
| Score | 100/100 | 65/100 |
| Peer rank and all 500 US records (CSV) | 🔒 Click to unlock → | |
| Official source URLs for every peer record | 🔒 Click to unlock → | |
Official records: Merck Sharp & Dohme LLC · Pfizer
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.